BRCA2 pathogenic variants carriers have 44.0, 3.69, 3.34 and 2.22-fold elevated lifetime risk of the male breast, stomach, pancreatic and prostate cancers compared to non-carriers, respectively (5). The gene discussed is BRCA2; the disease is prostate carcinoma.